California-based International Stem Cell Corp. announced that Dr. Simon Craw, the company’s Executive Vice President of Business Development, will attend and present at the SeeThru Equity Fall Smallcap & Microcap Conference, to be held at the Cornell Club in midtown Manhattan, New York, on Tuesday, October 2, 2012.
International Stem Cell is a biotechnology company focused on therapeutic and research products. The company has developed a powerful new stem cell technology called parthenogenesis that promises to advance the field of regenerative medicine by addressing the problem of immune-rejection.
Risk of rejection for stem cell therapeutics is proportional to the degree of difference between the immune system proteins present on the donated cells and the immune system proteins present on the cells of the recipient. The human leukocyte antigen (HLA) system is the term used for antigens important for transplantation. Normally donor tissue is screened for these immune system proteins (antigens) in order to determine the degree of compatibility with the recipient.
Parthenogenetic stem cells are pluripotent human stem cells that come from unfertilized oocytes (eggs). Because of the way they are generated, parthenogenetic stem cells have a duplicate set of human leukocyte antigen (HLA) genes, which greatly reduces the possibility of the derived cells being rejected by an individual’s immune system, meaning that a single cell line can be suitable for the treatment of millions of individuals. As such, a small number of cell lines could be sufficient to provide “immune matched” cells to a significant percentage of the world’s population. ISC has already created the first parthenogenetic stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of different genders, ages, and racial backgrounds, with minimal immune rejection after transplantation.
The company also offers specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, in addition to stem cell-based skin care products through its subsidiary Lifeline Skin Care.
For additional information on ISCO, visit the company’s website at www.InternationalStemCell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment